Sentences with phrase «synuclein antibodies»

Not exact matches

PRX002: Targeting C - Truncated Alpha - Synuclein When we last reported news from Prothena Corp PLC, their cofounder and CEO Dr. Dale Schenk had recently presented the results of studies using their AS - targeting antibodies at SENS Research Foundation's Rejuvenation Biotechnology 2014 conference.

In a previous post, we surveyed an exciting new development in rejuvenation biotechnology: the sudden emergence and rapid progress toward the clinic of vaccine - and antibody (Ab)- based immunotherapy to remove α - synuclein aggregates from the aging brain.

5a: Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney G, Koller M, Ness DK, Griffith S, Grundman M, Soto J, Ostrowitzki S, Boess F, Martin - Facklam M, Quinn J, Isaacson S, Jennings D, Omidvar O, Ellenbogen A. Results From a Phase 1b multiple ascending - dose study of PRX002, an anti — alpha - synuclein monoclonal antibody, in patients with Parkinson's disease [abstract].

Antibody - aided clearance of extracellular α - synuclein prevents cell - to - cell aggregate transmission.

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Prothena Corporation plc (NASDAQ: PRTA), announced today that they have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha - synuclein, including PRX002... which is currently in preclinical development and is expected to enter Phase 1 clinical trials in patients with Parkinson's disease in 2014.